Search research articles
Contact Us
Filters
Showing results (1-10 of 32) with videos related to
Page
of 4
Sort By:
Current Oncology (Toronto, Ont.)
|
October 1, 2010
Research in castration-resistant prostate cancer: what does the future hold?
R J Macfarlane, K N Chi
Journal of Clinical Epidemiology
|
May 17, 2000
The standard of reporting of health-related quality of life in clinical cancer trials
C W Lee, K N Chi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2000
Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo
H Miyake, K N Chi, M E Gleave
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
May 11, 2013
The future of systemic therapies for localised prostate cancer
B J Eigl, M E Gleave, K N Chi
Current Oncology (Toronto, Ont.)
|
May 3, 2019
Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis
E S Tsang, C Forbes, K N Chi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 16, 2013
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
K L Noonan, S North, R L Bitting, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2009
Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy
C Kollmannsberger, C Moore, K N Chi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 28, 2009
A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer
J Michels, S L Ellard, L Le, et al.
Current Oncology (Toronto, Ont.)
|
September 5, 2008
Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group
W R Parulekar, M McKenzie, K N Chi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 8, 2010
Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies
C Kollmannsberger, S Tyldesley, C Moore, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 32) with videos related to
Sort By:
Page
of 4
Current Oncology (Toronto, Ont.)
|
October 1, 2010
Research in castration-resistant prostate cancer: what does the future hold?
R J Macfarlane, K N Chi
Journal of Clinical Epidemiology
|
May 17, 2000
The standard of reporting of health-related quality of life in clinical cancer trials
C W Lee, K N Chi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2000
Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo
H Miyake, K N Chi, M E Gleave
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
May 11, 2013
The future of systemic therapies for localised prostate cancer
B J Eigl, M E Gleave, K N Chi
Current Oncology (Toronto, Ont.)
|
May 3, 2019
Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis
E S Tsang, C Forbes, K N Chi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 16, 2013
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
K L Noonan, S North, R L Bitting, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2009
Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy
C Kollmannsberger, C Moore, K N Chi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 28, 2009
A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer
J Michels, S L Ellard, L Le, et al.
Current Oncology (Toronto, Ont.)
|
September 5, 2008
Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group
W R Parulekar, M McKenzie, K N Chi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 8, 2010
Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies
C Kollmannsberger, S Tyldesley, C Moore, et al.
Page
of 4